- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02364323
Genetic Testing and Counseling to Reduce Diabetic Complications
A Randomized Clinical Trial to Compare a Strategy Utilizing Genetic Testing and Personalized Risk Counseling With Standard Care on Patient Empowerment, Risk Factors Control and the Risk of Diabetic Complications
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Asia is in the midst of an epidemic of diabetes. Approximately 1 in 10 people in China has diabetes [1]. Asian patients with diabetes are characterized by early age of onset and increased risk of kidney complications. Young age of onset and long disease duration will place Chinese diabetic patients at high risk for complications. In the Hong Kong Diabetes Registry, which includes more than 7000 patients with type 2 diabetes, we have reported a high risk of diabetic complications, with 30% having died or sustained a major clinical event within 10years after diagnosis, including 10% developing cardiovascular complications, and 10% developing end-stage renal disease [2] [3]. The medical costs for the diabetic patient with complication is 2.2-3.8 fold that of patients without complications, and patients with cardiorenal complications are the most costly to manage [4]. Using our registry, we have identified clinical risk predictors for developing renal complications as glycaemic control, elevated blood pressure, hyperlipidaemia, and albuminuria [2] [3, 5], and have derived clinical risk prediction algorithms and incorporated them into a patient management portal, which can generate a standardized report for risk counseling based on clinical risk factors [6, 7]. Furthermore, in a multi-centre study utilizing a multidisciplinary team, we found that intensive management aiming to achieve targets of A1c, lipids, BP can significantly reduce the risk of developing kidney complication [8]. Therefore, the ability to identify subjects at risk of complications, and to target and motivate them to optimize modifiable risk factors for diabetic complications will be of clinical benefit and potentially cost-saving.
There has been much recent interest in the use of genetic testing for personalized medicine [9]. Diabetic kidney complications has high heritability of around 40% and several genetic factors have been found to be associated with diabetic renal complications. Using candidate-gene approach, our group has identified several genetic markers for diabetic kidney complications [10, 11] [12]. These include the angiotensin converting enzyme deletion/ insertion (ACE D/I) polymorphism and the aldose reductase (ALR2) 5'-(CA) n microsatellite polymorphism, each being associated with 2-3 fold increased risk of diabetic cardio-renal complications in Chinese [10, 13]. More recently, we have found that carriers of risk alleles at the protein kinase C-β1 (PRKCB1) locus can have up to 6-fold increased risk of developing end-stage renal disease during follow-up, after adjusting for the effect of clinical risk predictors [12].
The recent increase in consumer-initiated genetic testing has been driven by direct-to-consumer genetic testing, which assumes that personal genetic information can motivate positive behavioural change in patients [14]. Interestingly, a recent survey of patients without type 2 diabetes suggests that genetic testing may be able to motivate patients, with 71% of respondents reporting that they would be "much more motivated" to make behavioural changes if they were informed to be of high genetic risk for diabetes [15]. Although evidence that genetic testing can lead to behavioural changes is still lacking, several randomized clinical trials are currently underway to examine the impact of genetic testing on behaviour to reduce risk of diabetes. Given the disabling consequences of diabetic complications, and the ability to predict those at risk of developing complications, we plan to examine the role of personalized risk counseling incorporating genetic markers, and to examine its role in patient empowerment and risk factor control, which may help to reduce the risk of developing complications.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
Shatin, Hong Kong
- Prince of Wales Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Adults with type 2 diabetes aged 40-75 who can give informed consent
- Subjects with no known chronic kidney disease (CKD defined as eGFR<60ml/min at baseline)
- Suboptimal glucose control with HbA1c ≥ 7.5%
- Known history of hypertension including elevated BP ≥140/90 on more than one occasion
Exclusion Criteria:
- Subjects with known coronary artery disease or coronary revascularisation
- Subjects with previous history of cerebrovascular accident
- Subjects with known proliferative retinopathy or previous laser treatment for diabetic retinopathy
- Subjects with life-threatening conditions including malignancy
- Subjects with known psychiatric conditions including depression
- Subjects with significant renal impairment (eGFR<60ml/min at baseline) or non-diabetic renal disease (e.g. biopsy-proven glomerulonephritis or obstructive uropathy)
- Subjects with major physical disability
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Helsetjenesteforskning
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Personalized risk counselling
Intervention includes risk counseling to patients with diabetes on future risk of diabetic complications based on an established genetic counseling framework for common polygenic disorders which will be delivered to patient in a counselling sesssion 6 weeks after genetic testing
|
Motivational message- towards lifestyle change, improved compliance and risk factors control Review overall control of clinical risk factors based on lab test results
|
Placebo komparator: Normal usual care
Intervention includes normal usual care.
General education on diabetes and diabetic complications
|
General education on diabetes and diabetic complications
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
percentage of patients attaining ≥ 3 pre-defined treatment targets from the following treatment targets: 1) BP <130/80 mm Hg 2) HbA1c <7% 3) Calculated LDL-cholesterol <2.6mmol/l 4) Fasting TG <2mmol/l 5) Use of ACEI or ARB
Tidsramme: At 1 year
|
primary outcome of 3 out of 5 targets achieved as defined above
|
At 1 year
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
microalbuminuria as a marker of degree of renal damage
Tidsramme: At 1 year
|
new onset of microalbuminuria at 1 year follow-up
|
At 1 year
|
Patient empowerment as measured on the Chinese Diabetes Empowerment Scale (DES)
Tidsramme: At 1 year
|
Score on the DES
|
At 1 year
|
Patient behavior measured on the Summary of Diabetes Self-care Activities (SDSCA)
Tidsramme: At 1 year
|
Score of diabetes self-care as measured by the SDSCA
|
At 1 year
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Ronald C Ma, MB BChir, Chinese University of Hong Kong
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, Shan Z, Liu J, Tian H, Ji Q, Zhu D, Ge J, Lin L, Chen L, Guo X, Zhao Z, Li Q, Zhou Z, Shan G, He J; China National Diabetes and Metabolic Disorders Study Group. Prevalence of diabetes among men and women in China. N Engl J Med. 2010 Mar 25;362(12):1090-101. doi: 10.1056/NEJMoa0908292.
- Chan BS, Tsang MW, Lee VW, Lee KK. Cost of Type 2 Diabetes mellitus in Hong Kong Chinese. Int J Clin Pharmacol Ther. 2007 Aug;45(8):455-68. doi: 10.5414/cpp45455.
- Chan JC, So W, Ma RC, Tong PC, Wong R, Yang X. The Complexity of Vascular and Non-Vascular Complications of Diabetes: The Hong Kong Diabetes Registry. Curr Cardiovasc Risk Rep. 2011 Jun;5(3):230-239. doi: 10.1007/s12170-011-0172-6. Epub 2011 Apr 12.
- Ko GT, So WY, Tong PC, Le Coguiec F, Kerr D, Lyubomirsky G, Tamesis B, Wolthers T, Nan J, Chan J. From design to implementation--the Joint Asia Diabetes Evaluation (JADE) program: a descriptive report of an electronic web-based diabetes management program. BMC Med Inform Decis Mak. 2010 May 13;10:26. doi: 10.1186/1472-6947-10-26.
- Chan J, So W, Ko G, Tong P, Yang X, Ma R, Kong A, Wong R, Le Coguiec F, Tamesis B, Wolthers T, Lyubomirsky G, Chow P. The Joint Asia Diabetes Evaluation (JADE) Program: a web-based program to translate evidence to clinical practice in Type 2 diabetes. Diabet Med. 2009 Jul;26(7):693-9. doi: 10.1111/j.1464-5491.2009.02751.x.
- Chen S, Chiu H, Xu B, Ma Y, Jin T, Wu M, Conwell Y. Reliability and validity of the PHQ-9 for screening late-life depression in Chinese primary care. Int J Geriatr Psychiatry. 2010 Nov;25(11):1127-33. doi: 10.1002/gps.2442.
- Yang XL, So WY, Kong AP, Clarke P, Ho CS, Lam CW, Ng MH, Lyu RR, Yin DD, Chow CC, Cockram CS, Tong PC, Chan JC. End-stage renal disease risk equations for Hong Kong Chinese patients with type 2 diabetes: Hong Kong Diabetes Registry. Diabetologia. 2006 Oct;49(10):2299-308. doi: 10.1007/s00125-006-0376-3. Epub 2006 Aug 30.
- Luk AO, So WY, Ma RC, Kong AP, Ozaki R, Ng VS, Yu LW, Lau WW, Yang X, Chow FC, Chan JC, Tong PC; Hong Kong Diabetes Registry. Metabolic syndrome predicts new onset of chronic kidney disease in 5,829 patients with type 2 diabetes: a 5-year prospective analysis of the Hong Kong Diabetes Registry. Diabetes Care. 2008 Dec;31(12):2357-61. doi: 10.2337/dc08-0971. Epub 2008 Oct 3.
- Chan JC, So WY, Yeung CY, Ko GT, Lau IT, Tsang MW, Lau KP, Siu SC, Li JK, Yeung VT, Leung WY, Tong PC; SURE Study Group. Effects of structured versus usual care on renal endpoint in type 2 diabetes: the SURE study: a randomized multicenter translational study. Diabetes Care. 2009 Jun;32(6):977-82. doi: 10.2337/dc08-1908.
- Malandrino N, Smith RJ. Personalized medicine in diabetes. Clin Chem. 2011 Feb;57(2):231-40. doi: 10.1373/clinchem.2010.156901. Epub 2010 Dec 2.
- Wang Y, Ng MC, So WY, Tong PC, Ma RC, Chow CC, Cockram CS, Chan JC. Prognostic effect of insertion/deletion polymorphism of the ace gene on renal and cardiovascular clinical outcomes in Chinese patients with type 2 diabetes. Diabetes Care. 2005 Feb;28(2):348-54. doi: 10.2337/diacare.28.2.348.
- Wang Y, Luk AO, Ma RC, So WY, Tam CH, Ng MC, Yang X, Lam V, Tong PC, Chan JC. Predictive role of multilocus genetic polymorphisms in cardiovascular disease and inflammation-related genes on chronic kidney disease in Type 2 diabetes--an 8-year prospective cohort analysis of 1163 patients. Nephrol Dial Transplant. 2012 Jan;27(1):190-6. doi: 10.1093/ndt/gfr343. Epub 2011 Jul 15.
- Ma RC, Tam CH, Wang Y, Luk AO, Hu C, Yang X, Lam V, Chan AW, Ho JS, Chow CC, Tong PC, Jia W, Ng MC, So WY, Chan JC. Genetic variants of the protein kinase C-beta 1 gene and development of end-stage renal disease in patients with type 2 diabetes. JAMA. 2010 Aug 25;304(8):881-9. doi: 10.1001/jama.2010.1191.
- So WY, Wang Y, Ng MC, Yang X, Ma RC, Lam V, Kong AP, Tong PC, Chan JC. Aldose reductase genotypes and cardiorenal complications: an 8-year prospective analysis of 1,074 type 2 diabetic patients. Diabetes Care. 2008 Nov;31(11):2148-53. doi: 10.2337/dc08-0712. Epub 2008 Aug 20.
- Janssens AC, Gwinn M, Bradley LA, Oostra BA, van Duijn CM, Khoury MJ. A critical appraisal of the scientific basis of commercial genomic profiles used to assess health risks and personalize health interventions. Am J Hum Genet. 2008 Mar;82(3):593-9. doi: 10.1016/j.ajhg.2007.12.020.
- Grant RW, Hivert M, Pandiscio JC, Florez JC, Nathan DM, Meigs JB. The clinical application of genetic testing in type 2 diabetes: a patient and physician survey. Diabetologia. 2009 Nov;52(11):2299-2305. doi: 10.1007/s00125-009-1512-7. Epub 2009 Sep 2.
- Ting RZ, Nan H, Yu MW, Kong AP, Ma RC, Wong RY, Loo K, So WY, Chow CC, Ko GT, Wing YK, Chan JC. Diabetes-related distress and physical and psychological health in chinese type 2 diabetic patients. Diabetes Care. 2011 May;34(5):1094-6. doi: 10.2337/dc10-1612. Epub 2011 Mar 11.
- Shiu AT, Martin CR, Thompson DR, Wong RY. Psychometric properties of the Chinese version of the diabetes empowerment scale. Psychol Health Med. 2006 May;11(2):198-208. doi: 10.1080/13548500500286845.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- GEM Study
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Diabetisk komplikasjon
-
Biotronik AGFullførtPerifer arteriesykdom | Access Site Complication | Poliklinisk behandlingFrankrike, Østerrike, Belgia, Sveits
-
Kahramanmaras Sutcu Imam UniversityFullførtOvervekt, sykelig | Peroperativ komplikasjon | BMD | Laparascopic Sleeve Gastrectomy | Fedmekirurgi Dødelighetspoeng | Clavien Dindo Surgical Complication Scale
-
Assiut UniversityUkjentom Vitreomacular Interface Abnormalities in Diabetic Retinopathy
Kliniske studier på Personalized Risk Counselling
-
Sun Yat-sen UniversityFullført
-
Temple UniversityUkjentStillesittende livsstil | Sigarett røykingForente stater
-
Steadman Philippon Research InstituteTilbaketrukket
-
Chinese University of Hong KongFullført
-
National Taiwan University HospitalUkjent
-
China-Japan Friendship HospitalUkjent
-
The Methodist Hospital Research InstituteRekruttering
-
Children's Healthcare of AtlantaRekruttering
-
Northwestern UniversityHar ikke rekruttert ennå
-
Louisiana State University Health Sciences Center...FullførtFysisk aktivitet | Metabolsk syndrom | Inflammatorisk respons | Astma hos barn | Fedme, barndom | Dårlig ernæring | Oppførsel, spising | Mors eksponering | Molekylærbiologi, restriksjonsfragmentlengdepolymorfismer | Genetisk endringForente stater